June 2025 in “Stem Cell Research & Therapy” This review highlights recent advancements in androgenetic alopecia treatment, focusing on the dysregulated signaling pathways involved in hair follicle regeneration and exploring innovative therapeutic strategies, including small molecule modulators and gene editing technologies, which show promise in preclinical models.
August 2024 in “International Journal of Pharmaceutics” This study found that a specially designed water-in-oil microemulsion containing Panax notoginseng saponins improved hair density and other hair health indicators in mice with telogen effluvium and androgenetic alopecia, offering a promising multi-mechanism strategy for alopecia treatment with potentially fewer side effects than traditional methods.
August 2024 in “Journal of Controlled Release” In a study using an AGA mouse model, researchers observed that a novel topical gel combining hybrid extracellular vesicles, gold nanoparticles, and finasteride accelerated hair regrowth and improved hair quality more effectively than conventional minoxidil treatment, presenting a promising option with fewer side effects.
1 citations
,
July 2024 in “International Journal of Molecular Sciences” In this study, miR-181a was found to inhibit the proliferation and induction abilities of ovine dermal papilla cells by targeting the GNAI2 gene and affecting the Wnt/β-Catenin signaling pathway, highlighting its role in the regulation of hair follicle growth and development.
April 2024 in “Biomedicine & pharmacotherapy” This study observed that pilose antler extract promoted hair growth in mice with androgenetic alopecia by stimulating the hair follicle growth cycle via the SHH/GLI pathway activation and BMP/Smad pathway suppression.
1 citations
,
July 2022 in “British Journal of Dermatology” In this study, researchers identified key transcriptome changes in male androgenetic alopecia hair follicles, suggesting that HIF-1 pathway genes and Wnt pathway inhibitors could be potential therapeutic targets.
31 citations
,
August 2021 in “Stem Cell Research & Therapy” This review examines the life cycle, biomarkers, and functions of hair follicle stem cells, emphasizing their role in hair loss therapy and other skin and hair disorders, but reports no new clinical results.
23 citations
,
January 2021 in “Biomedicine & Pharmacotherapy” This study found that dihydrotestosterone induced hair loss and changes in hair morphology in male C57BL/6 mice, effects that could be partially reversed by the AR antagonist bicalutamide.
8 citations
,
October 2020 in “Stem cell research & therapy” This study found that DNMT1 promotes adipogenesis in hair follicle stem cells by regulating the miR-214-3p/MAPK1/p-ERK1/2 pathway, suggesting potential applications in stem cell therapy.
12 citations
,
July 2020 in “Aging” This study found that the enhancer of zeste homolog 2 (EZH2) may promote hair growth by increasing STK40 expression and facilitating hair follicle stem cell proliferation and differentiation.
71 citations
,
January 2019 in “International journal of biological sciences” This study proposes the miR-22-5p-LEF1 axis as a novel pathway that may regulate hair follicle stem cell proliferation.
153 citations
,
March 2017 in “Endocrine” This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.
52 citations
,
May 2015 in “PLOS Genetics” This study found that the microRNA miR-22 is a key regulator of the hair cycle, influencing hair loss by promoting the transition from growth to rest phases and repressing keratinocyte differentiation.
44 citations
,
April 2015 in “PubMed” This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.
43 citations
,
August 2014 in “Dermatologic Therapy” This study confirmed that a sulfotransferase enzyme test can effectively rule out 95.9% of nonresponders to 5% topical minoxidil for treating androgenetic alopecia.